Literature DB >> 23345473

Successful rechallenge with clozapine following 'red alert'.

Thelma K Toni-Uebari1, John Rees.   

Abstract

A case is presented of a 23-year-old lady with treatment-resistant schizoaffective disorder who had responded well to treatment with clozapine. Fifteen months after satisfactory use of clozapine she had 'red alerts' from routine haematological monitoring indicating neutropenia. Clozapine was discontinued and she was admitted to the psychiatric hospital to manage the aftermath of discontinuing clozapine and start alternative treatment with other antipsychotics. Her mental health rapidly deteriorated. Adequate trials with amisulpride, haloperidol, olanzapine and flupenthixol decanoate yielded little improvement in her clinical state. After 9 months of non-response to other antipsychotic medications, she was rechallenged with clozapine, followed by improvement in her mental state. She was eventually discharged home after 14 months of hospitalisation in a stable mental state. She remained mentally stable in the community on clozapine for 18 months after rechallenge, with no further red alerts.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23345473      PMCID: PMC3604197          DOI: 10.1136/bcr-2012-007172

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.

Authors:  J Munro; D O'Sullivan; C Andrews; A Arana; A Mortimer; R Kerwin
Journal:  Br J Psychiatry       Date:  1999-12       Impact factor: 9.319

2.  Blood dyscrasias in clozapine-treated patients in Italy.

Authors:  G Lambertenghi Deliliers
Journal:  Haematologica       Date:  2000-03       Impact factor: 9.941

3.  Rechallenge of late-onset neutropenia with clozapine.

Authors:  Joyce G Small; Mary C Weber; Marietta H Klapper; Jeffrey J Kellams
Journal:  J Clin Psychopharmacol       Date:  2005-04       Impact factor: 3.153

4.  Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia.

Authors:  Sharmin Ghaznavi; Marina Nakic; Paul Rao; Jian Hu; Judson A Brewer; Jonas Hannestad; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2008-07       Impact factor: 18.112

Review 5.  When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.

Authors:  Peter Manu; Deepak Sarpal; Owen Muir; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2011-11-22       Impact factor: 4.939

6.  Rechallenge with clozapine following leucopenia or neutropenia during previous therapy.

Authors:  Louisa R Dunk; Linda J Annan; Christopher D Andrews
Journal:  Br J Psychiatry       Date:  2006-03       Impact factor: 9.319

7.  Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.

Authors:  K Atkin; F Kendall; D Gould; H Freeman; J Liberman; D O'Sullivan
Journal:  Br J Psychiatry       Date:  1996-10       Impact factor: 9.319

8.  Mechanism of clozapine-induced agranulocytosis : current status of research and implications for drug development.

Authors:  M Pirmohamed; K Park
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

9.  Clozapine and granulocyte colony-stimulating factor: potential for long-term combination treatment for clozapine-induced neutropenia.

Authors:  Karen A Mathewson; J-P Lindenmayer
Journal:  J Clin Psychopharmacol       Date:  2007-12       Impact factor: 3.153

  9 in total
  1 in total

1.  Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review.

Authors:  Mina Boazak; Benjamin Kahn; Lindsay Cox; James Ragazino; David R Goldsmith; Robert O Cotes
Journal:  Clin Schizophr Relat Psychoses       Date:  2018-06-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.